Safety for medicines will be further reinforced with the introduction of new obligatory features like a unique identifier and an anti-tampering device, according to an announcement this morning from the European Commission.
Such safety features will protect European citizens against the health threat of falsified medicines, which may contain ingredients, including active ingredients of low quality or in the wrong dosage. The safety features will guarantee medicine authenticity for the benefit of patients and businesses, and will strengthen the security of the medicine supply chain - from manufacturers to distributors to pharmacies and hospitals.
The act in question, published today in the Official Journal, supplements the Falsified Medicines Directive (2011/62/EU), which aims to prevent falsified medicines to reach patients, to allow European Union citizens to buy medicines online through verified sources, and to ensure that only high quality ingredients are used for medicines in the EU. The delegated Regulation will enter into force three years after publication.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze